Ads by Google
Prostate Cancer Treatment and Symptoms
FDA should wait for the overall survival analysis of satraplatin for the treatment of hormone-refractory prostate cancer.
Primary care doctors should promote discussion of prostate cancer and personalized decisions about prostate cancer screening options.
Genaera Corporation and Cystic Fibrosis Foundation Therapeutics have agreed for reasons of futility to discontinue the Phase 2 study of LOMUCIN for the treatment of cystic fibrosis (CF).
Satraplatin - Prednisone Combination For Treatment Of Patients With Metastatic Hormone-Refractory Prostate Cancer
Pharmion submitted marketing authorization application Satraplatin in combination with prednisone for the treatment of patients with metastatic hormone-refractory prostate cancer who have failed prior chemotherapy.
Scientific findings suggest that pomegranates may one day find a place in healthful diets, benefit prostate cancer and heart.
For many men with early-stage prostate cancer, sorting out the treatment options can be overwhelming. The most important thing to do is to take your time and make sure you explore all prostate cancer treatment choices thoroughly.
Men who drink an average of four to seven glasses of red wine per week are only 52% as likely to be diagnosed with prostate cancer as those who do not drink red wine
Rockland County Department of Health encourages men to get tested for prostate cancer during a free screening this Saturday, June 16th from 11 a.m. - 3 p.m. at Nyack Hospital as part of a Health Fair.
The number of tumor cells circulating in the bloodstream of patients with metastatic, hormone-resistant, prostate cancer can predict how they will do with chemotherapy.
Novacea and Schering-Plough Corporation have entered into an exclusive worldwide license agreement for the development and commercialization of Asentar for prostate cancer treatment.
Cancer Center Karolinska have jointly developed a DNA Vaccine to stimulate a patient's immune system to fight and kill prostate cancer cells remaining in the body after removal or irradiation of the prostate gland.
EDAP TMS S.A. announced the continuation of its US Phase II/III clinical trial with treatment of an additional two patients at Virginia Urology Center, Richmond, Virginia.
This technology offers an alternative to other approved therapies for prostate cancer and may be effective in selected individuals as a primary therapy.
The unique application of operations research to the treatment of prostate cancer allowed Memorial Sloan-Kettering Cancer Center to better Fortune 500 companies and win an international competition for best project by an organization.
New studies of a blood protein recently identified at Johns Hopkins, early prostate cancer antigen-2 (EPCA-2), may change the way men are screened for prostate cancer - a disease that kills tens of thousands of men every year.
A rigorous, long-term study of quality of life in patients who underwent one of three common prostate cancer treatments found that each treatment affected men's lives in different ways.
A new prostate cancer research has been published by Onconome, Inc., which conducted a breakthrough prostate cancer study at The Johns Hopkins School of Medicine.
FDA has accepted for filing the Company's New Drug Application for satraplatin in combination with prednisone for patients with hormone-refractory prostate cancer whose prior chemotherapy has failed.
Researchers have identified a new imaging technique that can measure the effectiveness of treatment for prostate cancer that has spread to the bones.
A study has identified seven genetic risk factors-DNA sequences carried by some people but not others-that predict risk for prostate cancer.
Unpleasant urinary symptoms caused by an enlarged prostate are also known as benign prostatic hyperplasia (BPH).
The introduction of age-specific cut-offs for prostate-specific antigen (PSA) levels used in prostate cancer screening will reduce the number of unnecessary prostate biopsies in older men who naturally have higher levels of PSA than younger men.
Androgen deprivation therapy (ADT) has become a valuable weapon in the fight against prostate cancer.
Obese and overweight men who are diagnosed with prostate cancer by biopsy are more likely than healthy weight men to actually have a more aggressive case of the disease than the biopsy results would indicate.